Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

      Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients

      Medical Dialogues Bureau13 Nov 2018 3:53 PM IST
      Drug major Cipla Monday said it has received final approval from the US health regulator for Valganciclovir tablets, used in the treatment of viral...
      Zydus Cadila gets USFDA nod for Anti-Fungal Ointment

      Zydus Cadila gets USFDA nod for Anti-Fungal Ointment

      Medical Dialogues Bureau13 Nov 2018 3:43 PM IST
      New Delhi: Zydus Cadila said it has received final approval from the US health regulator to market Nystatin and Triamcinolone Acetonide Ointment, used...
      China mulls USD 720,000 fine for faking vaccine tests after scandal

      China mulls USD 720,000 fine for faking vaccine tests after scandal

      Medical Dialogues Bureau13 Nov 2018 9:42 AM IST
      Beijing: Chinese vaccine manufacturers who falsify test results or break other rules could be fined up to USD 720,000 under a new law proposed after a...
      Takeda sets vote date, aims to close $62 Billion Shire deal Jan. 8

      Takeda sets vote date, aims to close $62 Billion Shire deal Jan. 8

      Medical Dialogues Bureau13 Nov 2018 9:00 AM IST
      LONDON: Japan's Takeda Pharmaceutical will hold an investor vote on its $62 billion acquisition of Shire next month and aims to close the deal on Jan....
      New DRUG options, risk factors added to AHA Heart guidelines, details

      New DRUG options, risk factors added to AHA Heart guidelines, details

      Medical Dialogues Bureau12 Nov 2018 3:41 PM IST
      Higher risk patients are advised to first try statins in combination with ezetimibe, the generic version of Zetia, which lowers cholesterol by...
      Cipla gets USFDA nod for generic version of Voltran Gel

      Cipla gets USFDA nod for generic version of Voltran Gel

      Medical Dialogues Bureau12 Nov 2018 11:47 AM IST
      New Delhi: Drug major Cipla has received final approval from the United States Food and Drug Administration (USFDA) for, indicated for the relief of...
      Wockhardt Q2 net loss widens to Rs 23 Crore

      Wockhardt Q2 net loss widens to Rs 23 Crore

      Medical Dialogues Bureau12 Nov 2018 11:05 AM IST
      India business stood at Rs 455 crore in the quarter as against Rs 452 crore in the same period last year. It contributed 40 per cent of the global...
      USFDA completes inspection of Biocon Bengaluru plant with no observations

      USFDA completes inspection of Biocon Bengaluru plant with no observations

      Medical Dialogues Bureau12 Nov 2018 10:20 AM IST
      Zero ObservationNew Delhi: Biotechnology major Biocon has announced the US health regulator has completed the inspection of its new manufacturing...
      AstraZenecas Diabetic drug Farxiga curbs heart failure, kidney risks

      AstraZeneca's Diabetic drug Farxiga curbs heart failure, kidney risks

      Medical Dialogues Bureau12 Nov 2018 9:15 AM IST
      New Delhi: The biggest clinical trial so far to assess a new class of diabetes pills shows that AstraZeneca's Farxiga can prevent heart failure and...
      NPPA fixes ceiling price of Volini Max gel

      NPPA fixes ceiling price of Volini Max gel

      Medical Dialogues Bureau11 Nov 2018 11:55 AM IST
      New Delhi: Through a recent notice, National Pharmaceutical Pricing Authority (NPPA), has fixed the price of various formulations of Volini Maxx...
      U.S. regulators snip red tape for medical devices to curb opioid crisis

      U.S. regulators snip red tape for medical devices to curb opioid crisis

      Medical Dialogues Bureau11 Nov 2018 10:40 AM IST
      New Delhi: Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win...
      Glenmark to launch phase 1 trial in solid tumours for myeloma drug

      Glenmark to launch phase 1 trial in solid tumours for myeloma drug

      Medical Dialogues Bureau11 Nov 2018 10:20 AM IST
      An ongoing first-in-human, open-label, Phase 1 trial of GBR 1342 in multiple myeloma, is assessing the safety and tolerability of increasing doses of...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok